A biotechnology company focused on developing therapies for rare and life‑threatening diseases, particularly those involving the complement system of the immune response. Its flagship drugs, including Soliris and Ultomiris, became major treatments for ultra‑rare blood and neurological disorders and ...
2 members of Congress have disclosed 3 trades in Alexion Pharmaceuticals, Inc. (ALXN), a Healthcare company. The buy/sell breakdown shows 2 purchases versus 1 sale, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2014-02-26 | JAMES B. RENACCI | buy | $1K – $15K |
| 2014-02-26 | JAMES B. RENACCI | buy | $1K – $15K |
| 2014-01-27 | MICHAEL T. MCCAUL | sell | $15K – $50K |